Some new perspectives in heparin-induced thrombocytopenia type ii

Journal of Extra-Corporeal Technology

Volumn 33, Issue 3, 2001, Pages 193-196

  Koster, A ^a   Meyer, O ^a   Hetzer, R ^a   Kuppe, H ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DANAPAROID; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN; RECOMBINANT HIRUDIN; THROMBIN INHIBITOR; TIROFIBAN;

ANTICOAGULATION; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; DRUG CHOICE; HEART SURGERY; HEPARINIZATION; HUMAN; MORBIDITY; MORTALITY; THROMBOCYTOPENIA;

EID: 0034785266     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Heparin-induced thrombocytopenia in patients who undergo open heart surgery
2. Heparin-associated thrombocytopenia and thrombosis - Implications for perioperative management
3. Heparin-induced thrombocytopenia
4. Heparin-induced thrombocytopenia
5. A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia
6. First workshop for detection of heparin-induced antibodies: Validation of the heparin-induced platelet activation test (HIPA) in comparison with a PF4/heparin Elisa
7. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia
8. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery
9. High incidence of antiheparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery
10. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular weight heparin: Clinical implications for heparin-induced thrombocytopenia
11. Patients treated with unfractionated heparin during open-heart surgery are at high risk to form antibodies with heparin platelet factor 4 complexes
12. Presence of autoantibodies to interleukin 8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia
13. Rapid detection of heparin-induced platelet v antibodies with particle gel immunoassy (IDHPF4)
14. Cross-reactivity study of low-molecular-weight heparins and heparinoid in heparin-induced thrombocytopenia
15. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
16. Clinical experience with the combined treatment of thrombin inhibitors and GP IIb/IIIa inhibitors in patients with HIT
17. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia
18. Improved laboratory confirmation of heparin-induced thrombocytopenia type II. Time course of antibodies and combination of antigen and biologic assays
19. Management of patients with heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172)
20. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia
21. A new assay for point-of-care monitoring of heparin and heparinoid anti-Xa activity
22. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - Assessment of the whole blood ecarin clotting time
23. A quick assay for monitoring r-hirudin during cardiopulmonary bypass in patients with HIT II: Adaptation of the ecarin clotting time to the ACT II device
24. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II
25. Recombinant hirudin as an alternative to anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients
26. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: Assessment of different filter systems
27. Heparin-induced thrombocytopenia: Management of patients for open-heart surgery. Case reports describing the use of iloprost
28. Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: Use of heparin and epoprostenol combined with online-monitoring of platelet function
29. In vitro efficiency of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia
30. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum-induced activation of platelets
31. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet-mediated activation of human endothelial cells
32. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition
33. Tirofiban: A review of its use in acute coronary syndromes